Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is a common arrhythmia, particularly prevalent in the elderly population. Catheter ablation is a common treatment for AF, but post-ablation recurrence of arrhythmias remains a significant clinical challenge. Dapagliflozin, an SGLT2 inhibitor primarily used for the treatment of type 2 diabetes, has shown potential in the field of cardiology, particularly for treating heart failure patients. Some studies suggest that dapagliflozin may reduce cardiac workload, improve heart function, and could even help in the management of atrial fibrillation. Therefore, this study aims to explore whether dapagliflozin can reduce the recurrence of arrhythmias following atrial fibrillation catheter ablation.
Phase:
NA
Details
Lead Sponsor:
Xu Liu
Collaborators:
Hefei Binhu Hospital Second People's Hospital of Hefei City The First People's Hospital of Hefei The Second People's Hospital of Anhui Province